Search clinical trials for: Post-transplant Cyclophosphamide (PTCy)

Total 3970 results

Shanghai General Hospital, Shanghai Jiao Tong University...

Completed

ATG/PTCy in Haplo-PBSCT Randomized Controlled,Multi-center (ATG/PTCy)

Myeloid Tumor

China
Masonic Cancer Center, University of Minnesota

Not yet recruiting

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

Acquired Pure Red Cell Aplasia | Paroxysmal Nocturnal Hemoglobinuria | Severe Aplastic Anemia | Acquired Amegakaryocytic Thrombocytopenia
Shanghai Jiao Tong University School of Medicine
Shanghai Clinical Research Center

Not yet recruiting

Comparison of Different Dose of Post-transplantation Cyclophosphamide as Graft Versus Host Disease Prophylaxis

GVHD

China
St. Petersburg State Pavlov Medical University

Active, not recruiting

PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT (PTCyRuxo)

Acute Myeloid Leukemia | Acute Lymphoid Leukemia | Stem Cell Transplant Complications | Graft-versus-host-disease

Russian Federation
Ivan S Moiseev

Completed

Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT

Immune System Diseases | Lymphoma | Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Lymphocytic Leukemia | Acute Lymphoid Leukemia

Russian Federation
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Institutes of Health (NIH)

Completed

Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation

Hematologic Malignancies | Graft-Versus-Host Disease

United States
National Cancer Institute (NCI)
National Institute of Neurological Disorders and Stroke (NINDS)

Recruiting

Optimizing PTCy Dose and Timing

Hematologic Neoplasms | Graft Versus Host Disease

United States
Shanghai General Hospital, Shanghai Jiao Tong University...

Unknown

Low Dose ATG Plus Low Dose PTCy as GVHD Prophylaxis in Haplo-HSCT (ATG/PTCy)

Prophylaxis | Graft-versus-host-disease

China
Fundació Institut de Recerca de l'Hospital de la...

Recruiting

Influence of Timing PTCy in AlloSCT

Cyclophosphamide Toxicity | Allogenic Haematopoetic Transplantation

Spain
Masonic Cancer Center, University of Minnesota

Recruiting

PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation

Lymphoma | Myelodysplastic Syndromes | Acute Leukemia | Myeloproliferative Neoplasm

United States
St. Petersburg State Pavlov Medical University

Completed

PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis

Primary Myelofibrosis | Myeloproliferative Disorders

Russian Federation
Asan Medical Center

Active, not recruiting

HCT With PTCy in Higher-risk MDS

Patients With MDS, Acute Myeloid Leukemia (AML) Evolving From MDS, and Chronic Myelomonocytic Leukemia (CMML)

Korea, Republic of
Wake Forest University Health Sciences
Atrium Health Levine Cancer Institute

Recruiting

Factors Affecting Post-transplant Cyclophosphamide (PTCy) Efficacy

Leukemia, Not Otherwise Specified | Leukemia, Other

United States
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide for Rescuing Patients With Graft Failure (HaploRescue)

Hematologic Diseases | Allogeneic Hematopoietic Stem Cell Transplantation | Graft Failure
McMaster University
Sanofi; Ozmosis Research Inc.; Cell Therapy Transplant Canada

Recruiting

ATG Plus PTCy vs ATG for CGVHD Prophylaxis

Acute Leukemia | Myelodysplasia | Chronic Graft-versus-host-disease

Canada, Australia
Instituto Nacional de Cancer, Brazil

Not yet recruiting

PTCy and ATG for MSD and MUD Transplants

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Hodgkin Lymphoma | Acute Lymphoblastic Leukemia | Non-hodgkin Lymphoma
Ossium Health, Inc.
Center for International Blood and Marrow Transplant Research

Withdrawn

Cryopreserved MMUD BM With PTCy for Hematologic Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Leukemia | Acute Lymphocytic Leukemia | T-lymphoblastic Lymphoma | Acute Undifferentiated Leukemia | Acute Biphenotypic Leukemia
Masonic Cancer Center, University of Minnesota

Recruiting

Allo HSCT Using RIC and PTCy for Hematological Diseases

Follicular Lymphoma | Myelodysplastic Syndromes | Leukemia, Myeloid | Myelofibrosis | Burkitt Lymphoma | Marginal Zone Lymphoma | Acute Lymphocytic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Prolymphocytic Leukemia | Plasma Cell Leukemia | Myeloproliferative Neoplasm | Small Lymphocytic... and other conditions

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...

Recruiting

RIC alloBMT With Post-transplant Cyclophosphamide for Refractory Systemic Sclerosis

Systemic Sclerosis

United States
Federal Research Institute of Pediatric Hematology...

Recruiting

PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of Immunity

Inborn Errors of Immunity

Russian Federation
The First Affiliated Hospital of Soochow University

Recruiting

M-PTCy vs BuCy in Haploidentical HSCT for Acute Leukemia

Acute Leukemia

China
Nanfang Hospital of Southern Medical University

Unknown

PTCy-ATG vs ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis

Hematopoietic Stem Cell Transplantation

China
Nantes University Hospital

Not yet recruiting

Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation (CY-MET-RIC)

Hematologic Malignancy | Graft Versus Host Disease
St. Petersburg State Pavlov Medical University

Terminated

Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT

Myelodysplastic Syndromes | Leukemia, Chronic Myeloid | Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Russian Federation
Sichuan University

Unknown

Chidamide Plus PTCy/Cyclosporine to Prevent GVHD After Myeloablative Conditioning, Matched PBSCT

MDS | Leukemia, Acute

China
Henry Ford Health System

Recruiting

PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis

Graft Versus Host Disease

United States
Medical College of Wisconsin

Recruiting

De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis

Graft-versus-host Disease

United States
Siriraj Hospital

Not yet recruiting

The Comparison the CMV Infection and Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation Between Standard Regimen, Methotrexate Plus Cyclosporin A, and Post-transplant Cyclophosphamide-based Regimen (CMV)

CMV Infection or Reactivation After Allogenic HSCT
DKMS gemeinnützige GmbH

Recruiting

GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG (GRAPPA)

AML | MDS | Peripheral Blood Stem Cell Transplantation | Graft Vs Host Disease | CMML | MDS/MPN

Germany
University of Liege
Belgian Hematological Society

Recruiting

Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning (HLA)

Myelodysplastic Syndromes | Multiple Myeloma | Hodgkin Lymphoma | Non Hodgkin Lymphoma | Myeloproliferative Disorder | Chronic Lymphoid Leukemia | Acute Myeloid Leukemia in Remission | Myeloproliferative Syndrome | Chronic Myeloid Leukemia in Remission | Acute Lymphoid Leukemia in Remission

Belgium
University of Kansas Medical Center
In8bio Inc.

Recruiting

Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia

United States
King Faisal Specialist Hospital & Research Center

Recruiting

Comparing Post-Transplant Cyclophosphamide as GVHD Prophylaxis to Standard of Care for Acute Leukemia Patients (PTCy-PMAT)

Acute Myeloid Leukemia (AML) in Remission | Acute Lymphoblastic Leukemia (ALL) in Complete Remission

Saudi Arabia
Nantes University Hospital

Terminated

Post Transplant Cyclophosphamide (PTCY) as Sole Graft Versus Host Disease (GVHD) Prophylaxis for Matched Allotransplant: CYRIC (CYRIC)

Graft Versus Host Disease

France
Federal Research Institute of Pediatric Hematology...

Recruiting

Low Dose Treosulfan Based Conditioning Regimen and PTCy in HSCT for Nijmegen Breakage Syndrome

Nijmegen Breakage Syndrome

Russian Federation
Beijing 302 Hospital

Not yet recruiting

Combination of ATG-based Conditioning Regimen and PTCy for GVHD Prevention in Allo-HSCT After PD-1 Blockade

Hematological Malignancies | Graft-versus-host Disease
Medical College of Wisconsin
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Completed

TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801) (1703/1801)

Lymphoma | Acute Leukemia | Myelodysplasia | Chronic Myelogenous Leukemia (CML)

United States
National Cancer Institute (NCI)

Suspended

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome

Hematopoietic Stem Cell Transplantation | Immunodeficiency

United States
Center for International Blood and Marrow Transplant...
National Marrow Donor Program

Recruiting

HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis (OPTIMIZE)

Lymphoma | Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myelofibrosis | Chronic Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Chronic Myeloid Leukemia | Acute Leukemia | Myeloproliferative Neoplasm | Pro-Lymphocytic Leukemia

United States
National Cancer Institute (NCI)

Recruiting

Allogeneic Hematopoietic Stem Cell Transplantation With JSP191-Based Conditioning in Participants With GATA2 Deficiency

Immunodeficiency | GATA2

United States
Peking University People's Hospital
Sanofi

Recruiting

The Optimization of Haploidentical Hematopoietic Stem Cell Transplantation

Hematological Malignancy

China
Ossium Health, Inc.
Center for International Blood and Marrow Transplant Research

Recruiting

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Acute Leukemia | Acute Undifferentiated Leukemia | Acute Biphenotypic Leukemia

United States
National Research Center for Hematology, Russia

Not yet recruiting

Comparison of PT-Cy at a Dose of 25 mg/kg/Day and PT-Cy at a Dose of 50 mg/kg/Day in GVHD Prophylaxis (CY25)

Hematologic Malignancy | Graft Versus Host Disease | Cyclophosphamide Adverse Reaction
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide in Patients With Acquired Refractory Aplastic Anemia (HAPLO-EMPTY)

Refractory Idiopathic Aplastic Anemia | Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation
St. Petersburg State Pavlov Medical University

Recruiting

Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies (PTBCy)

Myelodysplastic Syndromes | Chronic Myeloid Leukemia | Myeloproliferative Neoplasm | Myeloid Leukemia, Acute

Russian Federation
Center for International Blood and Marrow Transplant...
National Marrow Donor Program

Recruiting

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide (ACCESS)

Lymphoma | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Acute Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Mixed Phenotype Acute Leukemia

United States
University of Sao Paulo General Hospital
Libbs Farmacêutica LTDA

Recruiting

GVHD Prophylaxis With Methotrexate in Haploidentical HCT Using Posttransplant Cyclophosphamide

Hematopoietic Neoplasm | Graft Vs Host Disease

Brazil
Baylor College of Medicine
National Cancer Institute (NCI)

Completed

Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies (DA-EPOCH-R)

Diffuse Large B Cell Lymphoma | Post Transplant Lymphoproliferative Disorder | Primary Mediastinal (Thymic) Large B-cell Lymphoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia

Recurrent Adult Burkitt Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Post-Transplant Lymphoproliferative Disorder | Recurrent Chronic Lymphocytic Leukemia | Recurrent Follicular Lymphoma and other conditions

United States
SCRI Development Innovations, LLC
Bristol-Myers Squibb

Withdrawn

Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Myelodysplastic Syndrome Acute Myeloid Leukemia

United States
Noah Merin
Teva Branded Pharmaceutical Products R&D, Inc.; Miltenyi Biomedicine GmbH

Active, not recruiting

Haploidentical Stem Cell Transplant With Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL

Lymphoma | Multiple Myeloma | Hodgkin Lymphoma | Chronic Lymphocytic Leukemia | CLL

United States

Search clinical trials for: Post-transplant Cyclophosphamide (PTCy)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations